New way to treat cancer.
We develop novel cancer therapeutics that effectively kill both dividing and non-dividing cancer cells to improve treatment response and prevent cancer recurrence.
We set a high bar to deliver a true clinical value.
Complete response
We target dividing and non-dividing (dormant) cancer cells to eliminate minimal residual disease.
New Complementary Mechanisms
We address cancer resistance via novel mechanism and ensure complementary effect with existing therapies.
Preventing recurrence
We integrate our treatment with standard of care to treat residual disease before it progresses.
Our mission is to improve patient survival by preventing cancer progression and recurrence.
20 million
New cancer cases annually worldwide
50%
Estimated risk of disease progression and mortality
“We want to give cancer survivors the confidence that their cancer won’t return, and to bring them and their families peace of mind.”
-Dr. Natasha Shtraizent, PhD, Co-founder and CEO of Frezent
About us
A multidisciplinary team of founders with deep scientific expertise, supported by an advisory board of proven leaders across biotech, business, and oncology therapeutics.
We partner with leading hospitals and work with key opinion leaders in oncology.
Frezent is supported by SOSV, New York Ventures (Empire State Development) and funding from NSF-SBIR grant.
We have joined accelerator programs to catalyze our journey from bench toward clinic.
Join us
Reach out for partnerships, investment opportunities, or general inquiries.